Literature DB >> 31703119

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells.

Marco Ruella1,2,3, David M Barrett4, Olga Shestova1, Jessica Perazzelli4, Avery D Posey1,3,4,5, Seok Jae Hong1, Miroslaw Kozlowski1, Simon F Lacey1,6, J Joseph Melenhorst1,6, Carl H June1,2,3,6, Saar I Gill1,2,3.   

Abstract

Unintentional transduction of B-cell acute lymphoblastic leukemia blasts during CART19 manufacturing can lead to CAR19+ leukemic cells (CARB19) that are resistant to CART19 killing. We developed an anti-CAR19 idiotype chimeric antigen receptor (αCAR19) to specifically recognize CAR19+ cells. αCAR19 CAR T cells efficiently lysed CARB19 cells in vitro and in a primary leukemia-derived xenograft model. We further showed that αCAR19-CART cells could be used as an "antidote" to deplete CART19 cells to reduce long-term side effects, such as B-cell aplasia.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31703119      PMCID： PMC7019191          DOI： 10.1182/blood.2019001859

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  20 in total

1.  T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.

Authors:  Michael Kalos; Bruce L Levine; David L Porter; Sharyn Katz; Stephan A Grupp; Adam Bagg; Carl H June
Journal:  Sci Transl Med       Date:  2011-08-10       Impact factor: 17.956

2.  Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.

Authors:  Waleed Haso; Daniel W Lee; Nirali N Shah; Maryalice Stetler-Stevenson; Constance M Yuan; Ira H Pastan; Dimiter S Dimitrov; Richard A Morgan; David J FitzGerald; David M Barrett; Alan S Wayne; Crystal L Mackall; Rimas J Orentas
Journal:  Blood       Date:  2012-12-14       Impact factor: 22.113

3.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

Review 4.  Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Authors:  Sattva S Neelapu; Sudhakar Tummala; Partow Kebriaei; William Wierda; Cristina Gutierrez; Frederick L Locke; Krishna V Komanduri; Yi Lin; Nitin Jain; Naval Daver; Jason Westin; Alison M Gulbis; Monica E Loghin; John F de Groot; Sherry Adkins; Suzanne E Davis; Katayoun Rezvani; Patrick Hwu; Elizabeth J Shpall
Journal:  Nat Rev Clin Oncol       Date:  2017-09-19       Impact factor: 66.675

Review 5.  Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.

Authors:  Antonia Rotolo; Anastasios Karadimitris; Marco Ruella
Journal:  Leuk Lymphoma       Date:  2017-11-22

6.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Authors:  Marco Ruella; David M Barrett; Saad S Kenderian; Olga Shestova; Ted J Hofmann; Jessica Perazzelli; Michael Klichinsky; Vania Aikawa; Farzana Nazimuddin; Miroslaw Kozlowski; John Scholler; Simon F Lacey; Jan J Melenhorst; Jennifer J D Morrissette; David A Christian; Christopher A Hunter; Michael Kalos; David L Porter; Carl H June; Stephan A Grupp; Saar Gill
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

7.  Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.

Authors:  C Imai; K Mihara; M Andreansky; I C Nicholson; C-H Pui; T L Geiger; D Campana
Journal:  Leukemia       Date:  2004-04       Impact factor: 11.528

8.  Inducible apoptosis as a safety switch for adoptive cell therapy.

Authors:  Antonio Di Stasi; Siok-Keen Tey; Gianpietro Dotti; Yuriko Fujita; Alana Kennedy-Nasser; Caridad Martinez; Karin Straathof; Enli Liu; April G Durett; Bambi Grilley; Hao Liu; Conrad R Cruz; Barbara Savoldo; Adrian P Gee; John Schindler; Robert A Krance; Helen E Heslop; David M Spencer; Cliona M Rooney; Malcolm K Brenner
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

9.  Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.

Authors:  Elena J Orlando; Xia Han; Catherine Tribouley; Patricia A Wood; Rebecca J Leary; Markus Riester; John E Levine; Muna Qayed; Stephan A Grupp; Michael Boyer; Barbara De Moerloose; Eneida R Nemecek; Henrique Bittencourt; Hidefumi Hiramatsu; Jochen Buechner; Stella M Davies; Michael R Verneris; Kevin Nguyen; Jennifer L Brogdon; Hans Bitter; Michael Morrissey; Piotr Pierog; Serafino Pantano; Jeffrey A Engelman; Wendy Winckler
Journal:  Nat Med       Date:  2018-10-01       Impact factor: 53.440

10.  Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials.

Authors:  Bipulendu Jena; Sourindra Maiti; Helen Huls; Harjeet Singh; Dean A Lee; Richard E Champlin; Laurence J N Cooper
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240
View more
  11 in total

1.  Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells.

Authors:  Sjoukje J C van der Stegen; Pieter L Lindenbergh; Roseanna M Petrovic; Hongyao Xie; Mame P Diop; Vera Alexeeva; Yuzhe Shi; Jorge Mansilla-Soto; Mohamad Hamieh; Justin Eyquem; Annalisa Cabriolu; Xiuyan Wang; Ramzey Abujarour; Tom Lee; Raedun Clarke; Bahram Valamehr; Maria Themeli; Isabelle Riviere; Michel Sadelain
Journal:  Nat Biomed Eng       Date:  2022-08-08       Impact factor: 29.234

Review 2.  Application and Design of Switches Used in CAR.

Authors:  Paweł Głowacki; Piotr Rieske
Journal:  Cells       Date:  2022-06-13       Impact factor: 7.666

Review 3.  Late Effects after Chimeric Antigen Receptor T cell Therapy for Lymphoid Malignancies.

Authors:  Rajshekhar Chakraborty; Brian T Hill; Aneela Majeed; Navneet S Majhail
Journal:  Transplant Cell Ther       Date:  2020-12-21

Review 4.  The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice.

Authors:  Marco Cerrano; Marco Ruella; Miguel-Angel Perales; Candida Vitale; Danilo Giuseppe Faraci; Luisa Giaccone; Marta Coscia; Molly Maloy; Miriam Sanchez-Escamilla; Hesham Elsabah; Afraa Fadul; Enrico Maffini; Gianfranco Pittari; Benedetto Bruno
Journal:  Front Immunol       Date:  2020-05-12       Impact factor: 7.561

Review 5.  Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.

Authors:  Ying Gong; Roel G J Klein Wolterink; Jianxiang Wang; Gerard M J Bos; Wilfred T V Germeraad
Journal:  J Hematol Oncol       Date:  2021-05-01       Impact factor: 17.388

Review 6.  Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward.

Authors:  Pouya Safarzadeh Kozani; Pooria Safarzadeh Kozani; Fatemeh Rahbarizadeh
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561

Review 7.  Born to survive: how cancer cells resist CAR T cell therapy.

Authors:  Jean Lemoine; Marco Ruella; Roch Houot
Journal:  J Hematol Oncol       Date:  2021-11-22       Impact factor: 23.168

Review 8.  Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review.

Authors:  Lærke J B Brandt; Mike B Barnkob; Yale S Michaels; Julia Heiselberg; Torben Barington
Journal:  Front Immunol       Date:  2020-02-26       Impact factor: 7.561

Review 9.  The Chimeric Antigen Receptor Detection Toolkit.

Authors:  Yifei Hu; Jun Huang
Journal:  Front Immunol       Date:  2020-08-11       Impact factor: 7.561

10.  Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts.

Authors:  Concetta Quintarelli; Marika Guercio; Simona Manni; Iolanda Boffa; Matilde Sinibaldi; Stefano Di Cecca; Simona Caruso; Zeinab Abbaszadeh; Antonio Camera; Biancamaria Cembrola; Roselia Ciccone; Alberto Orfao; Lourdes Martin-Martin; Sara Gutierrez-Herrero; Maria Herrero-Garcia; Gianni Cazzaniga; Vittorio Nunes; Simona Songia; Paolo Marcatili; Frederikke I Marin; Marco Ruella; Valentina Bertaina; Luciana Vinti; Francesca Del Bufalo; Mattia Algeri; Pietro Merli; Biagio De Angelis; Franco Locatelli
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.